Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $937,500 with SRX Health Solutions, Inc. at 10% per annum maturing May 28, 2027.
- Instrument
- convertible notes
- Principal
- $937,500
- Counterparty
- SRX Health Solutions, Inc.
- Rate
- 10% per annum
- Maturity
- May 28, 2027
- Event
- incurrence
Exact text from the filing
On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Health Solutions, Inc. (“Lender”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to SRX Health Solutions, Inc. for $750,000.
- Security
- convertible note
- Purchaser
- SRX Health Solutions, Inc.
- Consideration
- $750,000
Exact text from the filing
On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Health Solutions, Inc. (“Lender”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. entered into Note with SRX Health Solutions, Inc. valued at $750,000 (effective 2026-05-28).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- SRX Health Solutions, Inc.
- Value
- $750,000
- Effective
- 2026-05-28
Exact text from the filing
On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to SRX Health Solutions, Inc. (“Lender”).
View on SEC.gov